Ascentage Pharma showcases novel drug candidates at AACR 2024
Ascentage Pharma (6855.HK), a prominent global biopharmaceutical firm, recently unveiled the latest preclinical study results for its innovative drug candidates at the American Association of Cancer Research Annual Meeting (AACR 2024) held in San Diego, California. This pivotal revelation underscores the company’s continued dedication to pioneering novel therapies for cancer, chronic hepatitis B (CHB), and […]